heart rhythm disorders

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Studies by Andrew Glazer, PhD, Giovanni Davogustto, MD, and colleagues found that genetic testing with information from electronic health records can reveal undiagnosed heart rhythm disorders.

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.